Glaucoma ignorance highlighted

Article

On World Sight Day, Windows to Health, the Pfizer UK initiative to promote regular eye test attendance, unveiled results of the All Eyes on Glaucoma survey, which highlighted the UK's ignorance around glaucoma and its prevention.

On World Sight Day, Windows to Health, the Pfizer UK initiative to promote regular eye test attendance, unveiled results of the All Eyes on Glaucoma survey, which highlighted the UK's ignorance around glaucoma and its prevention.

The survey, of UK adults aged ≥16 years (n=2297), demonstrated low levels of glaucoma awareness and attempts at disease prevention. The respondents reported poor rates of attendance at optician appointments; <50% had visited an optician in the last five years; approximately 20% will visit an optician only when a specific vision problem becomes apparent, and the same percentage is unclear as to the availability of (and their own eligibility for) free eye tests. Approximately one third of respondents were unaware of the symptoms of glaucoma, which may explain why an estimated half a million people in England and Wales suffer from the disease yet remain undiagnosed.

World Sight Day is an annual day of events to promote awareness of low vision and blindness. Although events are organized independently, the World Sight Day initiative - held on the second Thursday in October - is co-ordinated by the International Agency for the Prevention of Blindness (IAPB) and organized by VISION 2020, the campaign to eliminate preventable blindness by 2020.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.